Zai Lab hauls in $761M from Hong Kong IPO to push Ze­ju­la, more bud­ding can­di­dates in Chi­na — re­port

Zai Lab is set to net more than $761 mil­lion from its sec­ondary list­ing in Hong Kong af­ter pric­ing the IPO at $72.51 (HKD$562) — just a hair be­low its Nas­daq clos­ing price on Mon­day, Bloomberg and Nikkei Asian Re­view re­port­ed.

A pi­o­neer in bring­ing West­ern drugs to Chi­na, co-founder and CEO Saman­tha Du has more than tripled Zai Lab’s mar­ket cap in the three years it’s been pub­lic in the US. The HKEX list­ing is de­signed to fund R&D and com­mer­cial­iza­tion for the cur­rent port­fo­lio while fu­el­ing new in-li­cens­ing pacts, the biotech wrote in a fil­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER